Nabriva Therapeutics PLC – (NASDAQ:NBRV) Director Colin Md Broom acquired 10,177 shares of the stock in a transaction on Friday, August 30th. The stock was bought at an average cost of $2.03 per share, with a total value of $20,659.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Colin Md Broom also recently made the following trade(s):

  • On Wednesday, August 21st, Colin Md Broom sold 10,177 shares of Nabriva Therapeutics stock. The shares were sold at an average price of $2.07, for a total transaction of $21,066.39.

Nabriva Therapeutics stock traded up $0.04 during trading hours on Friday, hitting $2.06. The company had a trading volume of 1,366,978 shares, compared to its average volume of 2,790,362. The company has a debt-to-equity ratio of 0.56, a current ratio of 5.67 and a quick ratio of 5.67. Nabriva Therapeutics PLC – has a 1 year low of $1.12 and a 1 year high of $3.27. The company has a 50-day moving average price of $2.21 and a two-hundred day moving average price of $2.38.

Nabriva Therapeutics (NASDAQ:NBRV) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.04. Nabriva Therapeutics had a negative net margin of 3,602.24% and a negative return on equity of 139.52%. The business had revenue of $0.53 million during the quarter, compared to analyst estimates of $0.88 million. On average, research analysts forecast that Nabriva Therapeutics PLC – will post -1.1 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC raised its holdings in shares of Nabriva Therapeutics by 30.0% in the 2nd quarter. Commonwealth Equity Services LLC now owns 65,010 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 15,000 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in shares of Nabriva Therapeutics by 180.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 52,272 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 33,656 shares in the last quarter. A.R.T. Advisors LLC bought a new stake in shares of Nabriva Therapeutics in the 2nd quarter valued at about $90,000. Wells Fargo & Company MN bought a new stake in shares of Nabriva Therapeutics in the 2nd quarter valued at about $169,000. Finally, Morgan Stanley raised its holdings in shares of Nabriva Therapeutics by 52.9% in the 2nd quarter. Morgan Stanley now owns 265,418 shares of the biotechnology company’s stock valued at $645,000 after purchasing an additional 91,869 shares in the last quarter. Institutional investors and hedge funds own 3.10% of the company’s stock.

Several equities research analysts have issued reports on the stock. Northland Securities set a $13.00 price objective on shares of Nabriva Therapeutics and gave the company a “buy” rating in a research report on Friday, August 16th. Wedbush reissued an “outperform” rating and issued a $5.00 price objective on shares of Nabriva Therapeutics in a research report on Friday, August 9th. HC Wainwright set a $7.00 price objective on shares of Nabriva Therapeutics and gave the company a “buy” rating in a research report on Sunday, August 18th. Bank of America set a $6.00 price objective on shares of Nabriva Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 20th. Finally, BidaskClub cut shares of Nabriva Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the stock. Nabriva Therapeutics presently has an average rating of “Buy” and an average target price of $7.17.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Featured Article: How does new data get added to a blockchain?

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.